Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies

• DOI: 10.1186/s12890-021-01802-1
• Publication Date: 2022-01-10T00:02:46Z
• Authors: Yongpeng Ge; Hanbo Yang; Xinyue Xiao; Lin Liang; Xin Lu; Guochun Wang
• Keywords: Signal recognition particle

Abstract Objectives The purpose was to clarify the characteristics of interstitial lung disease (ILD) in immune-mediated necrotizing myopathy (IMNM) patients with anti-signal recognition particle (SRP) antibodies. Methods Medical records IMNM anti-SRP antibodies were reviewed retrospectively. Results A total 60 identified. Twenty-seven (45.0%) diagnosed ILD based on imaging: nonspecific pneumonia (NSIP) 17 (63.0%) and organizing 9 (33.3%). Reticulation pattern identified whereas 10 cases (37.0%) showed ground glass opacity patchy shadows by high-resolution computed tomography (HRCT). Pulmonary function tests (PFTs) available 18 patients, 6 (33.3%) (55.6%) included mild moderate group, respectively. average age at time onset significantly older than those without (48.6 ± 14.4 years vs. 41.2 15.4 years, p < 0.05), frequency dysphagia group higher ( 0.05). Long-term follow-up patients. PFTs stable 8 (88.9%), HRCT remained (66.7%) Conclusions is not rare antibodies, most being characterized as severity. NSIP principal radiologic pattern, typically remains following treatment.